(Boursier.com) — Theradiag announced the launch of ez-Track, a so-called “Point-of-Care Testing (POCT)” automaton allowing diagnostics to be carried out as close as possible to patients.
Marketed primarily in Europe under the Theradiag brand, ez-Track enables diagnoses to be made as close as possible to patients thanks to samples taken from the small blood vessels located around the fingernails (capillaries). This automaton then provides the results of these tests in a short time, which makes it possible to accelerate the implementation of the monitoring of biotherapies. Presented as “compact, easy to use and compatible with all the kits developed by Theradiag”, the ez-Track technological solution completes the Theradiag range which until now consisted of the Lisa Tracker and the i- Track.
The ez-Track system has received CE marking, which will allow a rapid launch of its commercialization. “The launch range consists of Infliximab and anti-Infliximab, as well as Adalimumab and anti-Adalimumab, all CE certified. diseases will quickly expand”, specifies Theradiag.
©2022 Boursier.com